Dihydroergotamine - Impel NeuroPharma

Drug Profile

Dihydroergotamine - Impel NeuroPharma

Alternative Names: DHE; Dihydroergotamine Mesylate; INP-104; POD-DHE

Latest Information Update: 23 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Impel NeuroPharma
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 22 Aug 2018 Phase-III clinical trials in Migraine in USA (Intranasal) (NCT03557333)
  • 22 Aug 2018 Impel NeuroPharma announces intention to submit NDA to the US FDA for Migraine in second half of 2019
  • 12 Jul 2018 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top